- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02237079
Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM) (BIM)
May 30, 2023 updated by: Franck Mauvais-Jarvis, Tulane University Health Sciences Center
The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women.
The recruitment will be performed at Tulane Health Sciences Center.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Clinical Translational Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Post-menopausal women (<5y since final menstrual period) with age between 50-60y
- Symptomatic (hot flashes, vaginal dryness) or asymptomatic
- BMI 26-45 kg/m2 (Overweight, Obesity I and Obesity II)
- Fasting glucose <125mg/dl
- Triglycerides <200mg/dl
- Normal mammogram within past 12 months
- Physician clearance
Exclusion Criteria:
- Amenorrhea from other causes (Hyperandrogenemia and anovulation)
- type 2 and type 1 diabetes
- Medications: diabetes or diabetic drugs, dyslipidemia, estrogen/progestin therapy, antidepressants and antipsychotics, antiretroviral (HIV), oral steroids, weight loss drugs
- ≤ 3 month washout of birth control pill (often prescribed for postmenopausal symptoms)
- Hysterectomy (partial or complete)
- Contraindications to estrogen treatment (unusual vaginal bleeding, blot clots, hepatic disease, bleeding disorder, past/present history of breast or uterine cancer, pregnant, breastfeeding)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bazedoxifene/Conjugated Estrogens (BZA/CE)
Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side.
The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals.
Tablets should be swallowed whole.
If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose.
They should not take two doses at the same time.
The dose is one tablet per day independent of weight and fat mass.
Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
|
Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
Other Names:
|
Placebo Comparator: Placebo
Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind.
Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side.
Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole.
If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose.
They should not take two doses at the same time.
The dose is one tablet per day independent of weight and fat mass.
Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind.
|
Daily placebo tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Mass Index
Time Frame: Change at 3 months from baseline
|
Body composition will be assessed through change in body mass index at baseline and at 3 months post-treatment.
|
Change at 3 months from baseline
|
Effect of CE/BZA on Body Composition Using Waist-to-hip Ratio
Time Frame: Change at 3 months from baseline
|
Body composition will be assessed through change in waist-to-hip ratio at baseline and at 3 months post-treatment.
|
Change at 3 months from baseline
|
Change in Body Composition Using Dual-energy X-ray Absorptiometry (DXA)
Time Frame: Change at 3 months from baseline
|
Dual-Energy X-ray Absorptiometry was used to assess body composition.
DXA uses an x-ray technique to look at the density of the body and can then estimate the amount of lean muscle mass and fat tissue.
Body composition will be assessed through change in DXA body composition at baseline and at 3 months post-treatment.
|
Change at 3 months from baseline
|
Change in Acute Insulin Response to Glucose (AIRg)
Time Frame: Change at 3 months from baseline
|
This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in acute insulin response to glucose.
IVGTT data derived by MINMOD Millennium software.
MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test.
Acute Insulin Response (AIRg) to Intravenous Glucose is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model.
AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection following glucose administration.
A low AIRg indicates decreased ability of the pancreas to secrete insulin.
|
Change at 3 months from baseline
|
Change in Basal Glucose Concentration (Gb)
Time Frame: Change at 3 months from baseline
|
This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in basal glucose concentration.
IVGTT data derived by MINMOD Millennium software.
|
Change at 3 months from baseline
|
Change in Disposition Index (DI)
Time Frame: Change at 3 months from baseline
|
Disposition index (DI) is the product of insulin sensitivity times the amount of insulin secreted in response to blood glucose levels.
DI is commonly used as a measure of β-cell function.
This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in disposition index (DI).
IVGTT data derived by MINMOD Millennium software.
DI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model.
DI is the product of insulin sensitivity and the amount of insulin secreted in response to blood glucose levels.
Disposition index is used as a measure of beta cell function and the ability of the body to dispose of a glucose load.
A low DI is indicative of a higher risk of developing diabetes.
|
Change at 3 months from baseline
|
Change in Insulin Sensitivity (SI) Index
Time Frame: Change at 3 months from baseline
|
SI indicates the net capacity for insulin to promote the disposal of glucose and to inhibit the endogenous production of glucose.
This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in insulin sensitivity (SI) index.
IVGTT data derived by MINMOD Millennium software.
SI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model.
SI is a measure of tissue response to circulating insulin in the blood following glucose injection.
A low SI signifies low insulin sensitivity and high SI represents high insulin sensitivity.
|
Change at 3 months from baseline
|
Change in Homeostatic Model Assessment (HOMA) β-cell Function
Time Frame: Change at 3 months from baseline
|
The homeostasis model assessment of β-cell function (HOMA-β) is an index of insulin secretory function derived from fasting plasma glucose and insulin concentrations.
This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) β-cell function.
(HOMA) β-cell function is a method used to quantify beta-cell function from fasting blood samples of insulin and glucose.
Normal levels for (HOMA) β-cell function is 107 or more.
Lower numbers mean higher risk of developing diabetes.
|
Change at 3 months from baseline
|
Change in Homeostatic Model Assessment (HOMA) Insulin Resistance (IR)
Time Frame: Change at 3 months from baseline
|
Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations.
This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) insulin resistance.
HOMA IR is a method used to quantify insulin resistance from fasting blood samples of insulin and glucose.
Normal levels for HOMA-IR is less than 2.0.
Higher levels mean higher risk for developing diabetes.
|
Change at 3 months from baseline
|
Change in Fasting Insulin Clearance (FIC)
Time Frame: Change at 3 months from baseline
|
This will be assessed at baseline and 3 months to measure the change in fasting insulin clearance (FIC).
FIC derived from fasting C-peptide to insulin ratio.
|
Change at 3 months from baseline
|
Change in Glucose-stimulated Insulin Clearance (GSIC)
Time Frame: Change at 3 months from baseline
|
This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in glucose-stimulated insulin clearance (GSIC).
GSIC derived from molar ratio of C-peptide to insulin area under curve (AUC) over first 20 min of IVGTT.
|
Change at 3 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure Change in Serum Biomarkers Panel 1
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in serum biomarkers (Leptin, Lipocalin 2 (LCN2), plasminogen activator inhibitor-1 (PAI-1), Intact OCN) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Measure Change in Serum Biomarkers Panel 2
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in serum biomarkers (Adiponectin, RBP4) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Measure Change in Leptin:Adiponectin Ratio (LAR)
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in leptin:adiponectin ratio (LAR) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Measure Change in Fibroblast Growth Factor-21 (FGF-21)
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in Fibroblast growth factor-21 (FGF-21) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Measure Change in C-Reactive Protein (CRP)
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in C-Reactive Protein (CRP) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Measure Change in Thiobarbituric Acid Reactive Substance (TBARS)
Time Frame: Change at 3 months from baseline
|
Systematic inflammation will be measured through change in Thiobarbituric acid reactive substance (TBARS) taken at baseline and 3 months.
|
Change at 3 months from baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Franck Mauvais-Jarvis, MD, Tulane University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2014
Primary Completion (Actual)
April 1, 2018
Study Completion (Actual)
April 1, 2018
Study Registration Dates
First Submitted
August 26, 2014
First Submitted That Met QC Criteria
September 9, 2014
First Posted (Estimated)
September 11, 2014
Study Record Updates
Last Update Posted (Actual)
June 26, 2023
Last Update Submitted That Met QC Criteria
May 30, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WI190523
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
At this time there is no plan to share individual participant data (IPD)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Bazedoxifene/Conjugated Estrogens (BZA/CE)
-
University of Kansas Medical CenterNational Cancer Institute (NCI)RecruitingBreast Cancer | Risk ReductionUnited States
-
Carol Fabian, MDActive, not recruitingIncreased Risk for Development of Breast CancerUnited States
-
VA Office of Research and DevelopmentNot yet recruitingObesity | Menopause | PrediabetesUnited States
-
PfizerCompletedEndometrial Hyperplasia | OsteoporosisUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedEndometrial Hyperplasia | Osteoporosis
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopauseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopause
-
University of Kansas Medical CenterPfizerCompletedBreast CancerUnited States